Daré Bioscience to Participate in Upcoming Virtual Conferences
- S&P, Nasdaq futures rise as JPMorgan, Goldman set to kick off earnings season
- JPMorgan (JPM) Reports a Q1 Beat on Revenue and Profit Fueled by Release of $5.2 Billion Reserved for Bad Loans; Shares Slightly Down
- Coinbase (COIN) direct listing IPO reference price set at $250
- Goldman Sachs (GS) Tops Q1 EPS by $8.38
- Wells Fargo (WFC) Tops Q1 EPS by 35c
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, its President and Chief Executive Officer, will participate in the following upcoming virtual conferences:
M Vest and Maxim Group Inaugural Emerging Growth Virtual ConferenceMarch 17-18, 2021Presentation available on-demand for event participants beginning Wednesday, March 17You may learn more about the event and register HERE.
BIO-Europe Spring DigitalMarch 22-25, 2021You may learn more about the event and register HERE.
A webcast of the company’s presentation at the M Vest and Maxim Group virtual conference will be available following the conference for two weeks under “Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.
About Daré Bioscience
Daré Bioscience is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women’s health. The company’s mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that expand treatment options, improve outcomes and facilitate convenience for women, primarily in the areas of contraception, vaginal health, sexual health, and fertility.
Daré’s product portfolio includes potential first-in-category candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive intravaginal ring whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra®; DARE-BV1, a unique hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy following menopause. To learn more about Daré’s full portfolio of women’s health product candidates, and mission to deliver differentiated therapies for women, please visit www.darebioscience.com.
Daré may announce material information about its finances, product candidates, clinical trials and other matters using the Investors section of its website (http://ir.darebioscience.com), SEC filings, press releases, public conference calls and webcasts. Daré will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product candidates, clinical trials and other matters. The information Daré posts on its investor relations website or through social media channels may be deemed to be material information. Daré encourages investors, the media, and others interested in the company to review the information Daré posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted on the investor relations page of Daré’s website mentioned above.
Investors on behalf of Daré Bioscience, Inc.:Tom MastersonAllele Capital Partnerstmasterson@allelecapital.com646.573.3216
Source: Daré Bioscience, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- APTN and FNHMA collaborate to bring weekly COVID-19 insights, you can watch on Saturdays 5:00pm on APTN
- Password manager NordPass adds many product improvements